AXSM at a glance
Axsome Therapeutics, Inc. (AXSM, SEC CIK 1579428) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Axsome Therapeutics, Inc. (AXSM) reported revenue of $638.5 million (up 65.5% from FY2024) and a net loss of $183.2 million. Diluted EPS was -$3.68.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Axsome Therapeutics, Inc. (AXSM) shares worth $4.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Jacobson Mark L. on September 3, 2026 of 10,000 shares at $208.65 per share.
- In the last 90 days, AXSM insiders reported 0 open-market purchases ($0) and 3 open-market sales ($12.6M) on Form 4, a net sale of $12.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $638.5M
- +65.5% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$12.6M
- 13F holders
- 36 funds
- $4.5B · +1 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 8.01 · Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Development, commercialization, and sales of pharmaceutical products for CNS disorders, including AUVELITY, SUNOSI, and launch of SYMBRAVO in 2025
- New product: Commercial launch of SYMBRAVO began June 2025, generating $6.6 million in net sales for the year, no sales in prior year
- Strategic shift: Expanded commercial focus from AUVELITY and SUNOSI to include SYMBRAVO, increasing total revenues 65.6% YoY to $638.5 million in 2025
- Quantitative metric: Net sales growth – AUVELITY sales up 74% to $507.1 million; SUNOSI up 33% to $120.1 million, total revenue increase from $385.7 million to $638.5 million
- Noteworthy fact: Recorded a significant decrease in net loss, $183.2 million in 2025 vs $287.2 million in 2024, reflecting scaling commercialization efforts
Risk Factors
- Regulatory risk: FDA Breakthrough Therapy designation for AXS-05 for AD agitation may not expedite approval or guarantee marketing authorization
- Geopolitical risk: EU sanctions on Russia extended to July 31, 2026, with potential supply chain and capital market disruptions impacting operations
- Supply chain risk: Dependence on third-party manufacturers subject to regulatory compliance and volume fulfillment could delay product commercialization
- Market disruption risk: Competition from other pharma, biotech firms, government agencies, and research organizations may impair operating results
- Financial risk: $570M Blackstone loan with restrictive covenants and minimum $30M liquidity may limit operational flexibility and risk default
AI summary of the AXSM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly heightened tariff risk: April 2026 proclamation imposes up to 100% tariffs on imported patented pharmaceuticals and ingredients
- Debt risk: Blackstone revolver commitments increased $20.0 million to $90.0 million, with minimum liquidity covenant of $30.0 million
- Regulatory risk: BIOSECURE Act restricts U.S. government procurement involving designated biotechnology companies of concern
- Operational risk: Tariff-driven supplier changes could disrupt manufacturing and derail commercialization plans
- Financial risk: Net loss reached $115.9 million for six months ended June 30, 2026, versus $107.4 million in 2025
AI summary of the AXSM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Updated corporate presentation posted August 10, 2026
- Exhibit 99.2 contains the presentation and may outline updated pipeline, strategy, or milestones
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for three months ended June 30, 2026, released August 10, 2026
- Operational update included alongside financial results
Item EX-99.1: Item EX-99.1
- Q2 net product revenue $218.4M, up 46% YoY, led by AUVELITY sales of $180.3M, up 51%
- Alzheimer’s agitation launch expands AUVELITY’s market; age 65+ new-to-brand prescriptions rose 126% in eight weeks
Item 8.01: Other Events
- FDA acceptance of AXS-12 NDA for cataplexy in narcolepsy advances Axsome’s regulatory pipeline
- Filing acceptance triggers FDA review, but does not indicate approval or commercial availability
Item EX-99.1: Item EX-99.1
- FDA accepted AXS-12 NDA for cataplexy in narcolepsy, advancing the candidate into regulatory review
- PDUFA target action date: May 1, 2027, establishing the next major catalyst
Item 5.07: Submission of Matters to a Vote of Security Holders
- 85.10% participation, with 43,777,536 of 51,439,952 eligible shares represented
- Mark Saad and Susan Mahony re-elected as Class II directors through 2029
AI summaries of AXSM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AXSM
Don't miss the next AXSM filing
- Alerts as it files. A push when AXSM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AXSM, by share count.
- Ask anything. An AI agent that reads every AXSM filing and answers with sources.
AXSM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Jacobson Mark L. | M | Sep 3, 2026 | 10,000 | - |
| Jacobson Mark L. | M | Sep 3, 2026 | 10,000 | $12.95 |
| Jacobson Mark L. | Sell | Sep 3, 2026 | 10,000 | $208.65 |
| TABUTEAU HERRIOT | Sell | Aug 6, 2026 | 4,660 | $213.95 |
| TABUTEAU HERRIOT | M | Aug 6, 2026 | 4,660 | - |
| TABUTEAU HERRIOT | M | Aug 6, 2026 | 4,660 | $4.95 |
| TABUTEAU HERRIOT | M | Aug 5, 2026 | 45,004 | $4.95 |
| TABUTEAU HERRIOT | Sell | Aug 5, 2026 | 45,004 | $212.01 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $385.7M | $638.5M |
| Operating Income | -$231.8M | -$280.6M | -$166.8M |
| Net Income | -$239.2M | -$287.2M | -$183.2M |
| Op. Margin | - | -72.7% | -26.1% |
| Net Margin | - | -74.5% | -28.7% |
| Balance Sheet | |||
| Total Assets | - | $568.5M | $689.8M |
| Equity | - | $57.0M | $88.3M |
| ROE | - | -503.8% | -207.5% |
| Per Share | |||
| EPS | $-5.27 | $-5.99 | $-3.68 |
| Cash Flow | |||
| Operating CF | -$145.1M | -$128.4M | -$93.4M |
| CapEx | - | $270K | $480K |
Source: XBRL data in Axsome Therapeutics, Inc. (AXSM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AXSM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $4.46B |
| Q1 2026 | 35 | $3.14B |
| Q4 2025 | 32 | $3.25B |
| Q3 2025 | 33 | $1.99B |
| Q2 2025 | 31 | $1.59B |
| Q1 2025 | 28 | $1.30B |
| Q4 2024 | 19 | $755.3M |
| Q3 2024 | 17 | $289.9M |
- Millennium Management+535.3K (+2579%)
- Invesco Ltd+374.0K (+29%)
- Two Sigma Investments+346.7K (+107%)
- Morgan Stanley+327.4K (+69%)
- Ameriprise Financial+251.8K (+143%)
- BlackRock−809.1K (-21%)
- T. Rowe Price Group−674.2K (-51%)
- State Street Corp−201.1K (-20%)
- Goldman Sachs Group−191.8K (-46%)
- Bank of America Corp−145.6K (-24%)
- Blackstone Group−24.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 231 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AXSM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | May 5, 2026 | - | - | - |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AXSM SEC filings: frequently asked questions
Are AXSM insiders buying or selling?
In the last 90 days, Axsome Therapeutics, Inc. (AXSM) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $12.6 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AXSM stock?
As of June 30, 2026, the largest Axsome Therapeutics, Inc. (AXSM) holders among the 13F filers tracked by SignalX were BlackRock ($759.7 million), Vanguard Portfolio Management LLC ($485.5 million), Vanguard Capital Management LLC ($481.0 million), Invesco Ltd ($409.2 million), FMR LLC (Fidelity) ($376.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AXSM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Axsome Therapeutics, Inc. (AXSM) reported revenue of $638.5 million (up 65.5% from FY2024) and a net loss of $183.2 million. Diluted EPS was -$3.68. The figures come from the XBRL data in the 10-K.
What are the main risks in AXSM's latest 10-K?
In the 10-K filed February 23, 2026, Axsome Therapeutics, Inc. (AXSM) flagged: Regulatory risk: FDA Breakthrough Therapy designation for AXS-05 for AD agitation may not expedite approval or guarantee marketing authorization. Geopolitical risk: EU sanctions on Russia extended to July 31, 2026, with potential supply chain and capital market disruptions impacting operations. (AI summary of the Risk Factors section.)
What did AXSM report in its latest 8-K?
Axsome Therapeutics, Inc. (AXSM) filed an 8-K on August 10, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Updated corporate presentation posted August 10, 2026.
What are the latest AXSM SEC filings?
Axsome Therapeutics, Inc. (AXSM) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on September 3, 2026.
What is AXSM's SEC CIK number?
Axsome Therapeutics, Inc. (AXSM)'s SEC Central Index Key (CIK) is 1579428. EDGAR lists every AXSM filing under that number.
Ask anything about AXSM
The research agent reads AXSM's filings, financials, insider trades and 13F holders, then answers with sources.